董事会认为，建议股份购回可提升股份价值，进而提高股东回报。此外，建议股份购回将彰显董事会对 其长期业务前景的信心，其将符合本公司及其股东的整体利益。董事会亦认为，本公司财务状况稳定， 可在进行建议股份购回的同时维持足够的财务资源以满足其持续业务增长需要。 绿茶集团(06831)发布公告，于2025年12月4日，董事会决议行使购回授权以适时于公开市场购回总价不 超过人民币1.3亿元的股份。建议股份购回的期间自董事会决议案日期起直至下列最早者：本公司下届 股东周年大会结束时、任何适用法律或本公司组织章程细则规定本公司须举行下届股东周年大会的期限 届满时或股东于股东大会上通过普通决议案撤销或修订本决议案所授予的授权时。本公司将动用其内部 资源(不包括全球发售所得款项净额)进行建议股份购回。本公司其后将在董事会认为适当的情况下注销 或以库存方式持有根据建议股份购回所购回的股份。本公司将根据本公司组织章程细则、香港联合交易 所有限公司证券上市规则、公司收购、合并及股份回购守则及所有其他适用法律法规进行建议股份购 回。 ...

Core Viewpoint - 朝聚眼科 (02219) announced a share buyback plan, reflecting confidence in its business outlook and aiming to create value for shareholders [1] Group 1: Share Buyback Announcement - The company plans to repurchase up to HKD 50 million worth of its shares starting from November 17, 2025 [1] - This decision is based on the approval from shareholders at the annual general meeting held on June 6, 2025 [1] - The board may increase the maximum repurchase amount depending on market conditions and will announce any changes in accordance with listing rules [1] Group 2: Market Reaction - Following the announcement, the stock price of 朝聚眼科 rose by 4.07%, reaching HKD 2.56, with a trading volume of HKD 1.3851 million [1]

Core Viewpoint - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan to repurchase up to HKD 50 million worth of its shares starting from November 17, 2025, following approval from shareholders at the annual general meeting on June 6, 2025 [1] Group 1 - The board believes that the share buyback demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] - The board may increase the maximum buyback amount based on market conditions, with timely announcements made as necessary according to listing rules [1] - The company asserts that its current financial resources are sufficient to implement the share buyback while maintaining a robust financial position [1]

Core Viewpoint - The company, Chaoyue Eye Care (02219), has announced a share buyback program, indicating confidence in its business outlook and potential to create value for shareholders [1] Summary by Sections Share Buyback Authorization - The board of directors has resolved to repurchase up to HKD 50 million worth of company shares starting from November 17, 2025, based on the authorization approved at the annual general meeting on June 6, 2025 [1] - The board may increase the maximum purchase amount under the buyback authorization depending on market conditions, with timely announcements to be made as necessary [1] Financial Position - The board believes that the company's existing financial resources are sufficient to implement the share buyback while maintaining a robust financial position [1]

Core Viewpoint - The company has updated its share buyback plan, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be below its true value [1] Group 1: Share Buyback Plan - The updated share buyback plan allows the company to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025 [1] - The total shares to be repurchased, including those already bought back in 2025, will represent 5% of the total issued shares as of the authorization date [1] Group 2: Management Confidence - The board believes that the share buyback plan reflects the confidence of the directors and senior management in the company's long-term growth and market performance [1] - The board asserts that the buyback plan is in the best interest of the company and its shareholders [1] Group 3: Shareholder Activity - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this purchase, the concert group holds a total of 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) [1] - The board views this increase in shareholding as a sign of confidence from major shareholders regarding the company's prospects and growth potential [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本 公 司 董 事 會（「董事會」）認 為 本 公 司 目 前 股 價 嚴重低估 本 公 司 的 價 值。憑 藉 對 本 公 司 未 來 發 展 前 景 的 充 分 信 心 及 對 本 公 司 內 在 價 值 的 高 度 認 同，為 持 續 增 強 市 場 對本公司的信心並提升本公司的投資價值，根據本公司股東於2025年6月20日舉行 的股東週年大會上 批 准 授 予 本 公 司 董 事（「董 事」）的股份購回授權，本公司已於2025 年11月6日至本公告日期在香港聯合交易所有限公司購回合共549,800股普通股作 為庫存股。所購回的股份佔本公司於本公告日期的現有已發行股份總數約0.24%。 於本公告日期，購回涉及的 總 金額為 約11.07百萬港元（不包括佣金及其他開支）。 股 東 及 潛 在 投 資 者 應 注 意，本 公 司 進 行 場 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 本公司董事（「董事」）會（「董事會」）有意宣佈，根據董事獲授出的一般授權（「股 份購回授權」，由股東於2025年6月12日舉行的股東週年大會上批准），董事會於 2025年11月7日決議不時自公開市場購回本公司普通股（「股份」），購回股份的金 額最高為30百萬港元。股份購回授權將持續有效，直至以下最早發生者為止：(i) 本公司下屆股東週年大會結束時；(ii)根據適用法律或本公司組織章程細則規定本 公司須舉行下屆股東週年大會期限屆滿時；或(iii)股東於本公司股東大會上以普 通決議案變更或撤銷該項授權時。股份購回授權的詳情載於本公司日期為2025年 5月21日的通函。 截至本公告日期，本公司根據股份購回授權購回1,681,000股股份並持作庫存股 份。股東及潛在投資者應注意，本公司之場內股份購回將視乎市況進行，並將由 董事會及╱或其授權人士全權酌情決定。概無法保證任何購回 ...

Core Viewpoint - The company plans to repurchase shares worth up to HKD 200 million in the open market, reflecting confidence in its business outlook and aiming to enhance shareholder returns [1] Group 1: Share Repurchase Details - The share repurchase will occur over a six-month period starting from the date of the announcement [1] - The total number of shares to be repurchased will not exceed 223 million shares, which is approximately 10% of the total shares issued as of the shareholders' annual meeting date [1] Group 2: Financial Health and Market Conditions - The company currently has a stable cash flow and overall financial condition, which supports its ongoing business development needs [1] - The board believes that the shares are undervalued in the market, justifying the repurchase decision [1]

Core Viewpoint - The company, Fenbi (02469.HK), intends to repurchase shares worth up to HKD 200 million in the open market over a six-month period, reflecting confidence in its business outlook and aiming to enhance shareholder returns [1] Group 1: Share Repurchase Plan - The board plans to buy back a total of up to approximately 223 million shares, which represents about 10% of the total shares issued as of the annual general meeting date [1] - The share repurchase will depend on market conditions and the company's financial arrangements [1] Group 2: Financial Health - The company currently has a stable cash flow and overall financial condition, which can support its ongoing business development needs [1] - The board believes that the shares traded in the market are undervalued, and the buyback will benefit the company and create value for shareholders [1]

Core Viewpoint - The company, 美丽田园医疗健康 (02373.HK), has repurchased shares, indicating management's confidence in the long-term value of the business and aiming to enhance shareholder returns [1] Summary by Relevant Sections Share Buyback Details - On October 27, 2025, the company repurchased 40,000 shares at a total transaction amount of approximately HKD 1,244,090, with an average price of about HKD 31.10 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 415,000 shares for approximately HKD 13,224,850 [1] Management's Perspective - The board believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The share buyback is seen as beneficial for the overall interests of the company and its shareholders, reinforcing management's commitment to the company's long-term value [1]